Sign In
Buy KURA
$8.66
-0.315 (-3.51%)
At Close: Jun 03, 2026
Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue Estimates
08:41am, Thursday, 05'th Mar 2026
Kura Oncology (KURA) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.22 per share a year ago.
Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
06:31am, Thursday, 05'th Mar 2026
– KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of zift
Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results
07:30am, Thursday, 26'th Feb 2026
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, toda
Kura Oncology to Participate in Three Upcoming Investor Conferences
07:30am, Wednesday, 25'th Feb 2026
SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, toda
Earnings Preview: Kura Oncology (KURA) Q4 Earnings Expected to Decline
11:05am, Wednesday, 18'th Feb 2026
Kura Oncology (KURA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Friday, 06'th Feb 2026
SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treat
Kura Oncology: Safety Profile Of Komzifti Supports My Upgrade To Strong Buy
07:34am, Thursday, 22'nd Jan 2026
Kura Oncology is upgraded from buy to strong buy, driven by a compelling valuation reset and robust cash position. Komzifti's FDA approval for relapsed/refractory NPM1-mutated AML is de-risked; the tr
New Strong Sell Stocks for January 21st
06:11am, Wednesday, 21'st Jan 2026
CRNT, KURA and CLSDQ have been added to the Zacks Rank #5 (Strong Sell) List on January 21, 2026.
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
05:00pm, Sunday, 11'th Jan 2026
– Launched KOMZIFTI ™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million KOMZIFTI net product revenue for the period f
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Monday, 05'th Jan 2026
SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treat
Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of “Moderate Buy” by Brokerages
01:46am, Monday, 15'th Dec 2025
Kura Oncology, Inc. (NASDAQ: KURA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the thirteen research firms that are currently covering the firm, Marketbeat.com reports. On
Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript
– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS – Median duration of complete response an
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
12:20pm, Thursday, 04'th Dec 2025
/PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells
Kura Oncology: A Cautious Buy
08:08am, Thursday, 04'th Dec 2025
Kura Oncology (KURA) is rated a cautious Speculative Buy, driven by Komzifti's FDA approval and frontline AML potential. KURA's near-term revenue under the current label is meaningful but insufficient
